Das US-Konkursgericht hat am 17. August 2022 die gemeinsame Verwaltung der Insolvenzverfahren nach Chapter 11 für Endo International plc und die mit ihr verbundenen Unternehmen angeordnet. Zu den verbundenen Unternehmen gehören Par Pharmaceutical, Inc, Actient Pharmaceuticals, LLC, 70 Maple Avenue, LLC, Anchen Incorporated, Generics International (US), Inc, Anchen Pharmaceuticals, Inc, DAVA Pharmaceuticals, LLC, Endo Par Innovation Company, LLC, Generics Bidco I, LLC, Innoteq, Inc, JHP Acquisition, LLC, JHP Group Holdings, LLC, Kali Laboratories, LLC, Moores Mill Properties L.L.C., Par Pharmaceutical Companies, Inc, Par Pharmaceutical Holdings, Inc, Par Sterile Products, LLC, Par, LLC, Quartz Specialty Pharmaceuticals, LLC, Quartz Specialty Pharmaceuticals, LLC, Actient Therapeutics LLC, Astora Women's Health Ireland Limited, Astora Women's Health, LLC, Auxilium International Holdings, LLC, Auxilium Pharmaceuticals, LLC, Auxilium US Holdings, LLC, Bermuda Acquisition Management Limited, BioSpecifics Technologies LLC, Branded Operations Holdings, Inc, DAVA International, LLC, Endo Aesthetics LLC, Endo Bermuda Finance Limited, Endo Designated Activity Company, Endo Eurofin Unlimited Company, Endo Finance IV Unlimited Company, Endo Finance LLC, Endo Finance Operations LLC, Endo Finco Inc. und Endo Generics Holdings, Inc, Endo Global Aesthetics Limited, Endo Global Biologics Limited, Endo Global Development Limited, Endo Global Finance LLC, Endo Global Ventures, Endo Global Ventures, Endo Innovation Valera, LLC, Endo Ireland Finance II Limited, Endo LLC, Endo Luxembourg Finance Company I S.à r.l., Endo Luxembourg Holding Company S.à r.l., Endo Luxembourg International Financing S.à r.l., Endo Management Limited, Endo Pharmaceuticals Finance LLC, Endo Pharmaceuticals Inc, Endo Pharmaceuticals Solutions Inc, Endo Pharmaceuticals Valera Inc., Endo Procurement Operations Limited, Endo TopFin Limited, Endo U.S. Inc, Endo US Holdings Luxembourg I S.à r.l., Endo Ventures Aesthetics Limited, Endo Ventures Bermuda Limited, Endo Ventures Cyprus Limited, Endo Ventures Limited, Generics International (US) 2, Inc., Generics International Ventures Enterprises LLC, Hawk Acquisition Ireland Limited, Kali Laboratories 2, Inc, Luxembourg Endo Specialty Pharmaceuticals Holding I S.à r.l., Paladin Labs Canadian Holding Inc., Paladin Labs Inc., Par Laboratories Europe, Ltd, Par Pharmaceutical 2, Inc., Slate Pharmaceuticals, LLC und Timm Medical Holdings, LLC. Die Fälle werden zu Verwaltungs- und Verfahrenszwecken gemeinsam verwaltet.

Endo International plc wurde als Hauptschuldner bestimmt.